Exceedingly rarely, the immunologic stress of Kikuchi disease can lead to hemophagocytic lymphohistiocytosis (HLH), which is a strong immunologic response associated with histiocytic proliferation, hemophagocytosis, systemic inflammatory response and disseminated intravascular coagulation that can be life-threatening with a mortality rate of 20-42%. HLH is managed with intravenous immunoglobulin and methylprednisolone, and pediatric outcomes are typically better than adults